VistaGen raises $3.75M for stem-cell derived drugs

South San Francisco, Calif.-based VistaGen Therapeutics, a biotech that uses human embryonic stem cells to discover new drugs, raised $3.75 million in a bridge financing as it prepares to raise up to $20 million in a fourth round. See our story in today’s briefing at VentureBeat Life Sciences.